Drugs / NewishT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05352646 | Jul 2022 → Jun 2024 | hepatocellular carcinoma | Newish Technology (Beijing) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NewishT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05352646 ↗ |
| Modality | Cell therapy | “autologous memory lymphocyte therapy (NewishT)” NCT05352646 ↗ |
| Route | Intravenous | “autologous memory lymphocyte (NewishT) intravenous infusion” NCT05352646 ↗ |